Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Letrozole (Femara) early and late responses to treatment

ABSTRACT: In the present investigation, we have exploited the opportunity provided by neoadjuvant treatment of a group of postmenopausal women with large operable or locally advanced breast cancer (in which therapy is given with the primary tumour remaining within the breast) to take sequential biopsies of the same cancers before and after 10-14 days or 90 days treatment with letrozole. RNA extracted from the biopsies has been subjected to Affymetrix microarray analysis and the data from paired biopsies interrogated to discover genes whose expression is most influenced by oestrogen deprivation. Keywords: Timecourse between subjects

ORGANISM(S): Homo sapiens

PROVIDER: GSE20181 | GEO | 2010/07/28

SECONDARY ACCESSION(S): PRJNA125655

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Letrozole (Femara) early and late responses to treatment

Project description:In the present investigation, we have exploited the opportunity provided by neoadjuvant treatment of a group of postmenopausal women with large operable or locally advanced breast cancer (in which therapy is given with the primary tumour remaining within the breast) to take sequential biopsies of the same cancers before and after 10-14 days or 90 days treatment with letrozole. RNA extracted from the biopsies has been subjected to Affymetrix microarray analysis and the data from paired biopsies interrogated to discover genes whose expression is most influenced by oestrogen deprivation. Keywords: Timecourse between subjects Biopsies were taken from the same subjects at three timepoints: pretreatment, after 10-14 days Letrozol (2.5 mg/day, oral), and after 90 days Letrozol (2.5 mg/day, oral).

2010-07-28 | E-GEOD-20181 | biostudies-arrayexpress

Letrozole (Femara) early response to treatment

Project description:In the present investigation, we have exploited the opportunity provided by neoadjuvant treatment of a group of postmenopausal women with large operable or locally advanced breast cancer (in which therapy is given with the primary tumour remaining within the breast) to take sequential biopsies of the same cancers before and after 10-14 days treatment with letrozole. RNA extracted from the biopsies has been subjected to Affymetrix microarray analysis and the data from paired biopsies interrogated to discover genes whose expression is most influenced by oestrogen deprivation. Keywords: time course

2007-12-10 | GSE5462 | GEO

Transcription profiling of human sequential breast cancer biopsies during letrozole treatment

Project description:In the present investigation, we have exploited the opportunity provided by neoadjuvant treatment of a group of postmenopausal women with large operable or locally advanced breast cancer (in which therapy is given with the primary tumour remaining within the breast) to take sequential biopsies of the same cancers before and after 10-14 days treatment with letrozole. RNA extracted from the biopsies has been subjected to Affymetrix microarray analysis and the data from paired biopsies interrogated to discover genes whose expression is most influenced by oestrogen deprivation. Experiment Overall Design: biopsies were taken from the same subjects both pretreatment and after 10-14 days Letrozol, 2.5 mg/day, oral

2008-06-13 | E-GEOD-5462 | biostudies-arrayexpress

Expression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days

Project description:breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo. We used microarrays to compare gene expression changes of MCF7 breast xenograft treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days

2011-11-02 | GSE33366 | GEO

Expression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days

2011-11-02 | E-GEOD-33366 | biostudies-arrayexpress

Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

Project description:Biopsies were collected from post-menopausal women with ER+ HER2- breast cancer who were subsequently treated with either letrozole or letrozole plus bevacizumab.

2019-12-19 | GSE142308 | GEO

Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole

Project description:Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole

| PRJNA272564 | ENA

Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole

Project description:<p>These are tumor biopsies and corresponding normal samples from patients with early stage ER+/HER2- breast cancer who had received the aromatase inhibitor letrozole for 10-21 days prior to surgery.</p>

| phs000857 | dbGaP

Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

Project description:Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

| PRJNA596523 | ENA

RNA sequencing of ER+ breast tumor treated with letrozole

Project description:Transcriptome of ER+ breast tumors treated with letrozole were profiled by RNA-seq

2020-07-01 | GSE145325 | GEO